REPCFライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (16 3月 2024 @ 00:20):

Stats
本日の出来高	550.00
平均出来高	2 461.00
時価総額	2.78M
EPS	$-0.0133 ( 2023-10-23 )
次の収益日	( $0 ) 2024-05-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.28
ATR14	$0 (0.00%)

RepliCel Life Sciences 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

RepliCel Life Sciences 財務諸表

Annual	2022
収益:	$353 735
総利益:	$353 735 (100.00 %)
EPS:	$-0.0341

FY	2022
収益:	$353 735
総利益:	$353 735 (100.00 %)
EPS:	$-0.0341

FY	2021
収益:	$353 735
総利益:	$0.00 (0.00 %)
EPS:	$-0.151

FY	2020
収益:	$353 735
総利益:	$0.00 (0.00 %)
EPS:	$-0.0600

Financial Reports:

No articles found.

RepliCel Life Sciences

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.